A week after a BC family went public with a plea for a life-changing drug for their son with cystic fibrosis (CF)The province has announced that they are offering Trikafta more widely.
10-year-old Oliver Narciso’s lung functions have declined since last year, and the boy’s family told Global News they are considering moving to Ontario to access a drug called “”change“For patients with CF.
‘Frustrating’: Family urges BC to fund new drug for young children with cystic fibrosis
Until now, the drug was only covered for patients 12 years of age and older. Without insurance, the drug costs $25,000 per month.
On Wednesday, the Department of Health announced it was expanding coverage for the drug, effective September 13, “based on recommendations from the Canadian Drug Experts Committee.”
Trikafta was first listed in September 2021, and the province says initial guidelines require patients to be 12 years of age or older and have a forced expiratory volume (FEV) of less than 90%.
Province expands Trikafta drug eligibility for young Manitobans
It says the guidelines have changed to include a younger cohort, with no requirements.
The changes will expand eligibility for children ages six to 11, and bring BC in line with other provinces.
“Today’s news will change the trajectory of the disease and the future for the many children and adults in British Columbia who are living with cystic fibrosis,” said Kelly Grover, president and chief executive officer of Cystic Fibrosis Canada. .
Vancouver couple leave to raise money for cancer drugs after insurance was denied by BC Cancer
“We are pleased to see that the starting point of restriction around lung function has also been removed, allowing more people to access the drug.”
Trikafta is covered through BC’s Expensive Drugs for Rare Diseases process, which gives patients access to high-priced drugs on a case-by-case basis.
About 150 people are currently eligible for the drug, with another 185 expected to be eligible when the criteria expand next week, the Department of Health said.
© 2022 Global News, a division of Corus Entertainment Inc.